Hello, everyone! 😊 Today, I’m sharing some exciting news from Yuhan Corporation, one of South Korea’s leading pharmaceutical companies. For the first time in its history, Yuhan has achieved annual sales exceeding 2 trillion KRW, making it the first traditional pharmaceutical company in Korea to reach this milestone. Let’s dive into the details!
📌 Yuhan Reports 2.0677 Trillion KRW in Sales
According to Yuhan Corporation’s latest disclosure, the company recorded:
✔ 2.0677 trillion KRW in total sales, up 11.2% from the previous year
✔ 476 billion KRW in operating profit, a 16.4% decrease
✔ 479 billion KRW in net profit, a 64.3% decline
The drop in operating profit was largely due to increased R&D expenses, as the company continued investing in new drug development. In 2024 alone, Yuhan spent 2.771 trillion KRW on research and development, a significant increase of 1.116 trillion KRW from the previous year.
💊 Key Growth Factors
1️⃣ Increased Licensing Revenue & Drug Sales
- Lazertinib (Lekraza), Yuhan’s non-small cell lung cancer treatment, was approved in the U.S. and Europe in combination with Johnson & Johnson’s Rybrevant.
- This led to 981 billion KRW in licensing revenue, marking a historic milestone as the first Korean anti-cancer drug approved in the U.S.
2️⃣ Strong Sales Across Key Products
- Antipuran (OTC pain relief ointment) → Sales increased 8.3% to 359 billion KRW
- Elena (probiotic supplement) → Sales rose 23.7% to 307 billion KRW
- Jardiance (diabetes treatment) → Sales grew 23.6% to 1.043 trillion KRW
- Twynsta (hypertension treatment) → Sales climbed 13.2% to 923 billion KRW
📈 Future Outlook
Yuhan Corporation is set to accelerate the global expansion of Lekraza, while also pursuing additional licensing deals to enhance profitability in 2025.
🚀 As Yuhan transitions from a leading domestic pharmaceutical company to a global player, it will be exciting to see how its R&D efforts and international expansion strategies unfold. Stay tuned for more updates on this growing industry leader! 😊
Thanks for reading, and I’ll be back with more interesting news soon! 💙
